Thymosin β4 in multiple myeloma: Friend or foe

Annals of the New York Academy of Sciences

Volumn 1194, Issue , 2010, Pages 125-129

  Caers, Jo ^a,b   Otjacques, Eleonore ^a   Hose, Dirk ^c,d   Klein, Bernard ^e   Vanderkerken, Karin ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c Nationales Centrum fur Tumorerkrankungen   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Multiple myeloma; Plasma cell; Thymosin beta 4

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; MELPHALAN; THYMOSIN BETA4; VINCA ALKALOID; THYMOSIN; THYMOSIN BETA(4);

ANGIOGENESIS; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CONFERENCE PAPER; DRUG MECHANISM; GENE OVEREXPRESSION; HUMAN; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PLASMA CELL; SOLID TUMOR; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BONE MARROW; GENETICS; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; REVIEW;

MURINAE; MUS;

ANIMALS; APOPTOSIS; BONE MARROW; HUMANS; MICE; MULTIPLE MYELOMA; THYMOSIN;

EID: 77951785354     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05470.x     Document Type: Conference Paper

References (25)

1. Goldstein, A.L. & M. Badamchian. 2004. Thymosins: Chemistry andbiological properties in health and disease. Expert Opin. Biol. Ther. 4: 559-573.
2. Hertzog, M. et al. 2004. The beta-thymosin/WH2 domain; structural basis for the switch from inhibition to promotion of actin assembly. Cell 117: 611-623.
3. Yarmola, E.G. & M.R. Bubb. 2004. Effects of profilin and thymosin beta4 on the critical concentration of actin demonstrated in vitro and in cell extracts with a novel direct assay. J. Biol. Chem. 279: 33519-33527.
4. Malinda, K.M., A.L. Goldstein & H.K. Kleinman. 1997. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J . 11: 474-481.
5. Philp, D. et al. 2006. Thymosin beta4 promotes matrix metalloproteinase expression during wound repair. J. Cell Physiol. 208: 195-200.
6. Smart, N. et al. 2007. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature 445: 177-182.
7. Clark, E.A. et al. 2000. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406: 532-535.
8. Nummela, P. et al. 2006. Thymosin beta4 is a determinant of the transformed phenotype and invasiveness of S-adenosylmethionine decarboxylase-transfected fibroblasts. Cancer Res. 66: 701-712.
9. Kobayashi, T. et al. 2002. Thymosin-beta4 regulates motility and metastasis of malignant mouse fibrosarcoma cells. Am. J. Pathol. 160: 869-882.
10. Wang, W.S. et al. 2004. Overexpression of the thymosin beta-4 gene is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma. Oncogene 23: 6666-6671.
11. Wang, W.S. et al. 2003. Overexpression of the thymosin beta-4 gene is associated with malignant progression of SW480 colon cancer cells. Oncogene 22: 3297-3306.
12. Cha, H.J., M.J. Jeong & H.K. Kleinman. 2003. Role of thymosin beta4 in tumor metastasis and angiogenesis. J. Natl. Cancer Inst. 95: 1674-1680.
13. Zhang, Y. et al. 2008. Thymosin beta 4 is overexpressed in human pancreatic cancer cells and stimulates proinflammatory cytokine secretion and JNK activation. Cancer Biol. Ther. 7: 419-423.
14. Ji, P. et al. 2003. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in earlystage non-small cell lung cancer. Oncogene 22: 8031-8041.
15. Grant, D.S. et al. 1995.Matrigel induces thymosin beta 4 gene in differentiating endothelial cells. J.Cell Sci. 108(Pt 12): 3685-3694.
16. Grant, D.S. et al. 1999. Thymosin beta4 enhances endothelial cell differentiation and angiogenesis. Angiogenesis 3: 125-135.
17. Smart, N., A. Rossdeutsch & P.R. Riley. 2007. Thymosin beta4 and angiogenesis:Modes of action and therapeutic potential. Angiogenesis 10: 229-241.
18. Caers, J. et al. 2008. Multiple myeloma-an update on diagnosis and treatment. Eur. J. Haematol. 81: 329-343.
19. Caers, J. et al. 2008. Unraveling the biology of multiple myeloma disease: Cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. Bull. Cancer 95: 301-313.
20. Vacca, A. et al. 1999. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93: 3064-3073.
21. Hose,D. et al. 2009. Induction of angiogenesis by normal and malignant plasma cells. Blood 114: 128-143.
22. Gondo, H. et al. 1987. Differential expression of the human thymosin-beta 4 gene in lymphocytes, macrophages, and granulocytes. J. Immunol. 139: 3840-3848.
23. Shimamura, R. et al. 1990. Expression of the thymosin beta 4 gene during differentiation of hematopoietic cells. Blood 76: 977-984.
24. Caers, J. et al. 2009. Thymosin {beta}4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma. Haematologica 95: 163-167.
25. Mahtouk, K. et al. 2005. Expression of EGF-family receptors and amphiregulin inmultiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene 24: 3512-3524.